Creative Bioarray, a global leader in the supply of research-use cells, including primary cells, tumor cells, stem cells and transformed cells, etc, has announced today the launch of new primary cells—Human B Cells to academic & pharmaceutical industries, as well as biotechnology organizations that are committed to biological research.
Creative Bioarray's HBC are cryopreserved immediately following purification
from HPBMC. Our HBC are quality tested via flow cytometry
to ensure proper expression of CD19 and depletion of undesired cell
types. HBC express CD19 but lack CD3, CD14 or CD56.
HBC are extensively tested for quality and optimal performance.
Creative Bioarray guarantees performance and quality.
"This newly released cells
provide researchers tools that can significantly contribute to diseases study," said said Dr. Hannah Cole, the senior scientific officer of R&D department of Creative Bioarray
. "These new lines also provide more convenience than currently available for assessment of compound toxicity
and efficacy, which can expedite drug
development and considerably reduce cost."
For more detailed information on the newly released Human B Cells
, please contact Creative Bioarray by calling 1-631-626-9181, or via e-mail at firstname.lastname@example.org.